Lucentis biosimilars access guide: ranibizumab biosimilar switching, buy-and-bill economics, retina interchangeability, and payer preference

Lucentis (ranibizumab injection, Genentech/Roche) was the first anti-VEGF therapy approved for intravitreal use in neovascular age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV). It now faces competition from three FDA-approved biosimilars — Byooviz, Cimerli, and Nufymco — plus continued pressure from off-label Avastin (bevacizumab) compounding and from Eylea/Eylea HD and Vabysmo.

This guide covers the ranibizumab biosimilar landscape as of mid-2026: which products carry interchangeability, how indication coverage differs, HCPCS coding, buy-and-bill economics, Avastin step therapy policies, and payer switching rules.

Quick comparison

Indication gaps that matter

Byooviz is approved only for nAMD, RVO-related macular edema, and mCNV — the three indications covered by the 0.5 mg vial. Because Byooviz does not have a 0.3 mg vial, it cannot carry the DME or DR indications, which are dosed at 0.3 mg per the Lucentis label. For retina practices that treat DME or DR patients, Cimerli and Nufymco are the only biosimilar options with full Lucentis indication parity.

Cimerli carries all five Lucentis indications in both the 0.3 mg and 0.5 mg formulations. It was the first ranibizumab biosimilar to receive an interchangeability designation at the time of its August 2022 approval.

Nufymco (ranibizumab-leyk), approved December 2025, carries interchangeability for all five Lucentis indications. It is supplied in 6 mg/mL and 10 mg/mL intravitreal injection presentations.

Interchangeability and pharmacy substitution

Three ranibizumab biosimilars now carry FDA interchangeability:

• Byooviz: Initially approved as a biosimilar only in September 2021. Interchangeability was granted by FDA in October 2023. Under interchangeability, a pharmacy may substitute Byooviz for Lucentis at the point of dispensing under state pharmacy practice laws, subject to any payer or prescriber override.
• Cimerli: Approved August 2022 with interchangeability from launch. It was the first ranibizumab biosimilar deemed interchangeable.
• Nufymco: Approved December 2025 with interchangeability for all Lucentis indications.

In retina practice, most ranibizumab is acquired through buy-and-bill by the physician office, not dispensed by a retail pharmacy. Interchangeability therefore matters less for automatic substitution at the pharmacy counter and more for payer formulary positioning. Payers increasingly treat interchangeable biosimilars as preferred products, with the originator requiring step-through or medical-exception documentation.

HCPCS coding

Ranibizumab and its biosimilars are billed on the medical benefit under Part B for Medicare and under the medical benefit for most commercial plans.

For a standard 0.5 mg intravitreal injection of Lucentis, bill J2778 × 5 units. For Byooviz 0.5 mg, bill Q5124 × 5 units. For Cimerli 0.3 mg, bill Q5128 × 3 units; for 0.5 mg, Q5128 × 5 units.

The administration code is CPT 67028 (intravitreal injection of a pharmacologic agent, separate procedure) with modifier LT (left eye), RT (right eye), or 50 (bilateral). Append JZ modifier for single-use vials with no waste, or JW modifier for documented wastage.

CMS confirms these codes in its Medicare coverage article for ranibizumab and biosimilars (A52451), grouping J2778, Q5124, Q5128 under Group 1 ICD-10-CM diagnosis codes.

Buy-and-bill economics

Retina practices typically acquire anti-VEGF agents through buy-and-bill: the practice purchases inventory from authorized specialty distributors, stores it under cold-chain requirements, and bills the drug plus administration on the medical claim.

Key economics for buy-and-bill ranibizumab products:

• Pricing: When Byooviz launched in June 2022, it was listed at approximately $1,130 per 0.05 mg single-use vial — roughly 40% below the Lucentis list price. Cimerli launched at $1,360 for the 0.5 mg vial and $816 for the 0.3 mg vial. Biosimilar pricing has continued to compress through 2025-2026 as more products enter.
• Medicare Part B: Reimburses at ASP + 6%. Biosimilar ASP is typically 15-35% below the reference product ASP. The spread between acquisition cost and ASP + 6% reimbursement drives practice margin, and biosimilar acquisition at a lower WAC can improve that margin — but only if the payer reimburses the Q-code at a rate that exceeds the acquisition price.
• Commercial payers: Reimbursement varies. Some payers reimburse biosimilar Q-codes at a percentage of billed charges, others at ASP + a contract-specific markup. Payer contracts that have not been updated to reflect biosimilar Q-codes may default to unclassified-biologic pricing, which is typically less favorable.
• Inventory risk: Ranibizumab products are single-use vials with cold-chain requirements. Practices that switch a portion of their ranibizumab volume to biosimilars must manage separate inventory for each product, since not all indications are interchangeable across biosimilar and reference.

Avastin step therapy

The most common access barrier for Lucentis and its biosimilars is Avastin-first step therapy. Avastin (bevacizumab), compounded for intravitreal use at a fraction of the cost, is required as first-line by many payers before covering any branded or biosimilar ranibizumab.

Payer step therapy patterns:

• Aetna (Medicare Advantage): Lucentis is non-preferred. Bevacizumab (Avastin, C9257) does not require precertification for ophthalmic use. Byooviz and Eylea are listed as preferred alternatives, but patients typically must demonstrate failure or contraindication to Avastin first.
• UnitedHealthcare: Requires prior authorization for ranibizumab products. Policies generally require documentation of prior intravitreal Avastin use, contraindication, or clinical reason for avoiding Avastin before approving ranibizumab or biosimilar.
• Cigna/HealthSpring: Coverage policy IP0543 requires documentation supporting the specific retinal diagnosis. Ranibizumab products (Byooviz, Cimerli, Lucentis) are considered medically necessary when applicable criteria are met, with continuation requiring documentation of beneficial response. Authorization duration is up to 12 months initial and renewal.
• Molina Healthcare: Coverage guideline C10417-A lists Lucentis, Byooviz, and Cimerli, with the recommendation that intravitreal injectable products be administered in a non-hospital facility-based location.

Harrow acquires Byooviz U.S. rights

On July 17, 2025, Harrow, Inc. announced an agreement with Samsung Bioepis to acquire the U.S. commercial rights to Byooviz (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy). Harrow specializes in ophthalmologic products and is expected to integrate Byooviz into its existing retina portfolio. This ownership change may affect distribution, pricing, and patient support programs for Byooviz starting in late 2025 and into 2026.

Cimerli ownership transition

Cimerli was originally developed and launched by Coherus BioSciences. In 2024, Sandoz (the generics and biosimilars division of Novartis, now an independent company) acquired the U.S. rights to Cimerli as part of a broader portfolio transaction. Sandoz now manages Cimerli distribution, pricing, and access support in the United States.

Payer switching and preferred-product policies

Payers are increasingly designating ranibizumab biosimilars as preferred products over the Lucentis reference:

• Independence Blue Cross: Updated biosimilar adoption policies in 2025 that include ranibizumab biosimilar preference, moving reference products to non-preferred status.
• Blue Cross Blue Shield of Michigan: For tocilizumab, the plan transitioned Actemra IV to non-preferred status with biosimilar preference; similar framework patterns apply to ranibizumab biosimilars in ophthalmology.
• Mass General Brigham Health Plan: Coverage policies typically require biosimilar use where available, with reference product requiring trial and failure of the biosimilar.

When a payer designates a ranibizumab biosimilar as preferred, practices switching from Lucentis to the biosimilar should verify:

1. The biosimilar carries the required indication (check DME/DR coverage if using Byooviz).
2. The HCPCS Q-code is recognized and reimbursable under the specific payer contract.
3. Authorization for current Lucentis therapy is transitioned proactively rather than requiring a new-start PA.

Reauthorization and continuation

Most payers approve initial ranibizumab product authorization for up to 12 months. Continuation requires documentation of:

• Beneficial clinical response (e.g., stable or improved visual acuity, OCT evidence of reduced macular thickness).
• Continued medical necessity for the specific retinal diagnosis.
• Appropriate dosing interval (not more frequent than once every 28 days per eye for most indications).

Reauthorization submissions should include OCT reports, visual acuity measurements, and clinical notes documenting treatment response.

Patient support programs

• Genentech Access Solutions: Supports patients prescribed Lucentis with benefit verification, prior authorization assistance, copay assistance, and patient assistance for eligible uninsured or underinsured patients.
• Byooviz: Patient support programs are transitioning under Harrow's U.S. commercialization. Check the Byooviz website (byooviz.com) for current enrollment and assistance options.
• Cimerli (Sandoz): Sandoz provides patient support including benefit verification and copay assistance. Enrollment is through the Sandoz biosimilar access program.

Sources

• FDA. Biosimilar Product Information. FDA list of approved biosimilar products including Byooviz, Cimerli, and Nufymco. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
• CMS. Billing and Coding: Ranibizumab and biosimilars, Aflibercept (Article A52451). https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52451
• Genentech. Lucentis billing and coding resources. https://www.lucentis.com/content/dam/gene/accesssolutions/pdfs/coding/LUCENTIS-Billing-Coding-for-ALL.pdf
• Cigna. Coverage Position IP0543: Ranibizumab Products. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0543_coveragepositioncriteria_ranibizumab.pdf
• Molina Healthcare. Ranibizumab and Biosimilars Coverage Guideline C10417-A. https://www.molinahealthcare.com/providers/oh/medicaid/policies/
• Pharmacy Times. FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar. December 2025. https://www.pharmacytimes.com/view/fda-approves-nufymco-interchangeable-ranibizumab-biosimilar-for-retinal-diseases
• Retina Specialist. How anti-VEGF biosimilars are changing retina care. https://www.retina-specialist.com/article/how-antivegf-biosimilars-are-changing-retina-care
• Big Molecule Watch. Harrow acquires Byooviz U.S. rights. July 2025. https://www.bigmoleculewatch.com/tag/ranibizumab
• Aetna. Ranibizumab and biosimilars clinical policy. https://www.aetna.com/cpb/medical/data/700_799/0799.html
• American Academy of Ophthalmology. Retina—Biosimilars, Dual Inhibitors, and Coding for New Drugs. https://www.aao.org/eyenet/article/retina-biosimilars-dual-inhibitors-and-coding
• PayerPrice. Ophthalmology & Retina Coding Guide. https://payerprice.com/blog/ophthalmology-billing-coding-guide